Phase II study of weekly cabazitaxel for ‘unfit’ metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. Circulating tumour cell (CTC) analysis (SOGUG-CABASEM Trial)
2014 ◽
Vol 32
(15_suppl)
◽
pp. e16034-e16034
2016 ◽
Vol 34
(6)
◽
pp. 760-770
◽
2014 ◽
Vol 32
(5)
◽
pp. 1005-1016
◽
2012 ◽
Vol 19
(1)
◽
pp. 215-224
◽